Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation

Abstract

IntroductionFunctional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine,a multimodal antidepressant, has shown encouraging data in achieving functional recovery, improving both mood and cognitive symptoms (Mahableshwarkar AR et al, 2015).ObjectivesThe aim of the study was to assess the effectiveness of vortioxetine on mood symptoms, cognitive symptoms and functionality, assessed by patient-rated tools, in MDD outpatients in Greece.MethodsIn this non-interventional study, vortioxetine was administered as flexible dosing (5-20 mg/d). Mood symptoms, cognitive symptoms and functioning were assessed by the patient-rated scales PHQ-9, PDQ-D and SDS respectively, at baseline, 1 and 3 months. Repeated measures analysis of variance and t-test were used for the statistical analyses.Results336 patients participated in the study. PHQ-9 score ±SD decreased from 16.1±5.3, to 10.0±5.7 and 4.6±4.5, PDQ-D score ±SD decreased from 37.3±16.6 to 23.1±14.8 and 12.0±10.6, SDS Score ±SD decreased from 18.7±5.3 to 12.9±5.9 and to 7.8±6.5, at baseline, 1 and 3 months, respectively. The 3 SDS subscales: work/school life improved from 5.8±2.4 to 4.2±2.2 and 2.6±2.2, social life improved from 6.6±2.0 to 4.5±2.2 and 2.7±2.3 and family life improved from 6.3±2.0 to 4.3±2.1 and 2.6±2.3 -baseline, 1 and 3 months, respectively (p<0.001 for all paired comparisons).ConclusionsMDD patients in Greece treated with vortioxetine significantly improved on mood symptoms, cognitive symptoms and functioning, enriching the already published efficacy data which is mostly based on clinician-rated scales.Conflict of interestA. Galanopoulos and E. Papalexi are full-time employees in Lundbeck Hellas.

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study

“…Similarly, a meta-analysis of data from nine short-term randomized placebo-controlled clinical trials of vortioxetine 5–20 mg found overall functioning to be significantly improved in patients with MDD treated with vortioxetine, with greatest effects seen at a dosage of 20 mg/day ( 50 ). The observed improvement in cognitive symptoms during treatment with vortioxetine in the present study is also consistent with previous findings both in open-label studies ( 16 , 50 – 53 ) and randomized controlled clinical trials ( 24 , 54 – 58 ). It seems reasonable to assume that the observed improvement in functioning seen in patients with MDD during treatment with vortioxetine may at least in part be due to the beneficial effect of treatment on cognitive symptoms.…”

“…The results of this large international study are in keeping with those of other small-scale studies in patients with MDD treated with vortioxetine in routine care settings ( 16 , 50 – 53 ). Similarly, a meta-analysis of data from nine short-term randomized placebo-controlled clinical trials of vortioxetine 5–20 mg found overall functioning to be significantly improved in patients with MDD treated with vortioxetine, with greatest effects seen at a dosage of 20 mg/day ( 50 ).…”

The effectiveness of vortioxetine in patients with depression in real clinical practice

“…В целом, результаты этого масштабного исследования согласуются с результатами имеющихся небольших исследований лечения БДР вортиоксетином в рутинной практике [13,18,19,30]. Аналогично, метаанализ данных девяти краткосрочных РКИ выявил улучшение общего функционирования пациентов с БДР, получавших лечение вортиоксетином в дозе 5-20 мг/сут, причем наибольший эффект наблюдался при применении препарата в дозе 20 мг/сут [12].…”

“…Прокогнитивное действие вортиоксетина, продемонстрированное в настоящем исследовании, согласуется с результатами многочисленных РКИ и открытых исследований [13,18,19,30].…”